# Successful pediatric heart transplantation with bivalirudin use in a cyanotic single ventricle patient with an intracorporeal continuous flow ventricular assist device and heparin-induced thrombocytopenia

**Authors:** Sandeep Sainathan, Leonardo Mulinari

PMC · DOI: 10.1007/s12055-024-01892-6 · 2025-01-07

## TL;DR

A child with a heart condition successfully underwent heart transplant using bivalirudin, managed with special support due to blood clotting issues.

## Contribution

Demonstrates successful management of bivalirudin-induced coagulopathy during pediatric heart transplant.

## Key findings

- Bivalirudin was used safely in a patient with heparin-induced thrombocytopenia during heart transplant.
- Coagulopathy was managed using extracorporeal membrane oxygenation and hemofiltration.
- Successful outcome achieved despite complex coagulation challenges.

## Abstract

We describe a case of profound coagulopathy during orthotopic heart transplantation in a cyanotic single ventricle pediatric patient with an intracorporeal continuous flow ventricular assist device performed on bivalirudin for heparin-induced thrombocytopenia. This was successfully managed with central veno-arterial extracorporeal membrane oxygenation and hemofiltration as an adjunct to treat bivalirudin-induced coagulopathy due to lack of a reversal agent for bivalirudin.

## Linked entities

- **Chemicals:** bivalirudin (PubChem CID 16129704)
- **Diseases:** heparin-induced thrombocytopenia (MONDO:0018048)

## Full-text entities

- **Diseases:** thrombocytopenia (MESH:D013921), coagulopathy (MESH:D001778)
- **Chemicals:** heparin (MESH:D006493)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12170461/full.md

---
Source: https://tomesphere.com/paper/PMC12170461